ZEISS Ventures and M2care back Maculaser's temperature-controlled retinal laser therapy
What's the deal? ZEISS VenturesDealroom has a profile for this one. Try Dealroom → has invested in MaculaserDealroom has a profile for this one. Try Dealroom →, a Finnish medtech startup developing non-damaging, temperature-controlled retinal laser therapy. The funding round, co-led by ZEISS Ventures and M2careDealroom has a profile for this one. Try Dealroom →, will support Maculaser's move into clinical development for its personalised retinal laser treatment.
Maculaser's technology, born from research at Aalto University, enables real-time temperature control of retinal tissue during laser treatment. It targets age-related macular degeneration (AMD) and diabetic maculopathy — conditions that threaten the vision of millions worldwide.
The goal: activate the eye's natural cellular defence mechanisms early, before irreversible damage occurs, potentially delaying or preventing progression to late-stage AMD.
Why now? Current treatments for retinal diseases largely manage late-stage damage rather than preventing it. Maculaser's approach aims to shift that paradigm toward proactive preservation of vision — intervening earlier with a repeatable, outpatient procedure that integrates into routine eye care.
ZEISSDealroom has a profile for this one. Try Dealroom →, which generated nearly €12B in revenue last fiscal year and invests 15% of that in R&D, sees the deal as aligned with its broader push into ophthalmic innovation and digital health.
"We are convinced that Maculaser's temperature-controlled retinal laser technology enables earlier intervention and could significantly delay — or even prevent — the progression of retinal diseases," said Prof. Dr. Boris Hofmann, head of ZEISS Ventures.
What could go wrong? The technology still needs to prove itself in clinical trials. Moving from patented lab research to approved medical treatment is a long, expensive road with no guaranteed outcome. Regulatory hurdles across different markets could further slow commercialisation.
Competition is also a factor. The ophthalmic treatment space is crowded, and incumbents with established therapies — including anti-VEGF injections — have deep market penetration.
The signal: Maculaser is still at the early growth stage, making ZEISS Ventures' co-lead a notable strategic bet — corporate venture arms rarely back pre-clinical medtech unless they see a clear path to integrating the technology into their own product ecosystem. With AMD alone affecting tens of millions globally and current standard-of-care options concentrated on late-stage management, even a modest shift toward preventive laser therapy could open a sizeable new market segment for ophthalmic device makers.
Read more: ZEISS
